Effects of non‐steroidal anti‐inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID‐19. Issue 8 (25th February 2022)

• Record Type: Journal Article
• Authors: Sokolowska, Milena; Rovati, G Enrico; Diamant, Zuzana; Untersmayr, Eva; Schwarze, Jürgen; Lukasik, Zuzanna; Sava, Florentina; Angelina, Alba; Palomares, Oscar; Akdis, Cezmi A.; O'Mahony, Liam; Jesenak, Milos; Pfaar, Oliver; Torres, María José; Sanak, Marek; Dahlén, Sven‐Erik; Woszczek, Grzegorz
• Is Part Of: Allergy. Volume 77:Issue 8(2022)
• Page Start: 2337
• Page End: 2354
• Publication Date: 2022-02-25
• Subjects: asthma -- biologicals -- COVID‐19 -- LTRA -- NSAID; Allergy -- Periodicals; 616.97
• DOI: 10.1111/all.15258
• Languages: English
• ISSNs: 0105-4538

Abstract

Abstract: Non‐steroidal anti‐inflammatory drugs (NSAIDs) and other eicosanoid pathway modifiers are among the most ubiquitously used medications in the general population. Their broad anti‐inflammatory, antipyretic, and analgesic effects are applied against symptoms of respiratory infections, including SARS‐CoV‐2, as well as in other acute and chronic inflammatory diseases that often coexist with allergy and asthma. However, the current pandemic of COVID‐19 also revealed the gaps in our understanding of their mechanism of action, selectivity, and interactions not only during viral infections and inflammation, but also in asthma exacerbations, uncontrolled allergic inflammation, and NSAIDs‐exacerbated respiratory disease (NERD). In this context, the consensus report summarizes currently available knowledge, novel discoveries, and controversies regarding the use of NSAIDs in COVID‐19, and the role of NSAIDs in asthma and viral asthma exacerbations. We also describe here novel mechanisms of action of leukotriene receptor antagonists (LTRAs), outline how to predict responses to LTRA therapy and discuss a potential role of LTRA therapy in COVID‐19 treatment. Moreover, we discuss interactions of novel T2 biologicals and other eicosanoid pathway modifiers on the horizon, such as prostaglandin D2 antagonists and cannabinoids, with eicosanoid pathways, in context of viral infections and exacerbations of asthma and allergic diseases. Finally, we identify and summarize the major knowledge gaps and unmet needs in current eicosanoid research. Abstract :